Cargando…

Current Clinical Applications of In Vivo Gene Therapy with AAVs

Hereditary diseases are caused by mutations in genes, and more than 7,000 rare diseases affect over 30 million Americans. For more than 30 years, hundreds of researchers have maintained that genetic modifications would provide effective treatments for many inherited human diseases, offering durable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendell, Jerry R., Al-Zaidy, Samiah A., Rodino-Klapac, Louise R., Goodspeed, Kimberly, Gray, Steven J., Kay, Christine N., Boye, Sanford L., Boye, Shannon E., George, Lindsey A., Salabarria, Stephanie, Corti, Manuela, Byrne, Barry J., Tremblay, Jacques P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854298/ https://www.ncbi.nlm.nih.gov/pubmed/33309881 http://dx.doi.org/10.1016/j.ymthe.2020.12.007

Ejemplares similares

Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy
por: Al-Zaidy, Samiah A., et al.
Publicado: (2015)

Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophy
por: Potter, Rachael A., et al.
Publicado: (2023)

AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy
por: Sahenk, Zarife, et al.
Publicado: (2014)

Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations
por: Mendell, Jerry R., et al.
Publicado: (2022)

Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer
por: Grose, William E., et al.
Publicado: (2012)

Improving retinal vascular endothelial cell tropism through rational rAAV capsid design
por: Periasamy, Ramesh, et al.
Publicado: (2023)

AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models
por: Sondergaard, Patricia C, et al.
Publicado: (2015)

Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines
por: Ryals, Renee C., et al.
Publicado: (2011)

A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy
por: Al-Zaidy, Samiah A., et al.
Publicado: (2017)

Advancements in AAV-mediated Gene Therapy for Pompe Disease
por: Salabarria, S.M., et al.
Publicado: (2020)

MicroRNA Based Treatment of Cardiomyopathy: Not all Dystrophies are Created Equal
por: Rodino‐Klapac, Louise R.
Publicado: (2013)

rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promoters
por: Beltran, William A., et al.
Publicado: (2010)

Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy
por: Willcocks, Rebecca J., et al.
Publicado: (2021)

Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6
por: Mellen, Russell W., et al.
Publicado: (2023)

Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS
por: Kanaan, Nicholas M., et al.
Publicado: (2017)

Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse
por: Gilkes, Janine A., et al.
Publicado: (2020)

A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy
por: Rodino-Klapac, Louise R, et al.
Publicado: (2007)

Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Potter, Rachael A., et al.
Publicado: (2021)

Targeted Gene Delivery to the Enteric Nervous System Using AAV: A Comparison Across Serotypes and Capsid Mutants
por: Benskey, Matthew J, et al.
Publicado: (2015)

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial
por: Mendell, Jerry R., et al.
Publicado: (2020)

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
por: Klimchak, Alexa C., et al.
Publicado: (2023)

Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
por: Kay, Christine N., et al.
Publicado: (2013)

Correction: Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors
por: Kay, Christine N., et al.
Publicado: (2013)

Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases
por: Perez, Barbara A., et al.
Publicado: (2020)

Evaluation of Lateral Spread of Transgene Expression following Subretinal AAV–Mediated Gene Delivery in Dogs
por: Bruewer, Ashlee R., et al.
Publicado: (2013)

Next-generation sequencing of mitochondrial targeted AAV transfer of human ND4 in mice
por: Yu, Hong, et al.
Publicado: (2013)

Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD
por: Wallace, Lindsay M., et al.
Publicado: (2017)

Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS
por: Goodwin, Marshall S., et al.
Publicado: (2020)

Dual-AAV vector-mediated expression of MYO7A improves vestibular function in a mouse model of Usher syndrome 1B
por: Lau, Samantha C., et al.
Publicado: (2023)

Evaluation of the Lipid-binding Properties of Recombinant Dystrophin Spectrin-like Repeat Domains R1-3
por: Cooper-Olson, Grace, et al.
Publicado: (2021)

Adeno-Associated Virus (AAV) Capsid Stability and Liposome Remodeling During Endo/Lysosomal pH Trafficking
por: Lins-Austin, Bridget, et al.
Publicado: (2020)

Persistent Expression of FLAG-tagged Micro dystrophin in Nonhuman Primates Following Intramuscular and Vascular Delivery
por: Rodino-Klapac, Louise R, et al.
Publicado: (2009)

Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model
por: Seo, Young-Eun, et al.
Publicado: (2023)

AAV retinal transduction in a large animal model species: Comparison of a self-complementary AAV2/5 with a single-stranded AAV2/5 vector
por: Petersen-Jones, S.M., et al.
Publicado: (2009)

Recombinant AAV-Mediated BEST1 Transfer to the Retinal Pigment Epithelium: Analysis of Serotype-Dependent Retinal Effects
por: Guziewicz, Karina E., et al.
Publicado: (2013)

Gauging Gait Disorders with a Method Inspired by Motor Control Theories: A Pilot Study in Friedreich’s Ataxia
por: Gouelle, Arnaud, et al.
Publicado: (2021)

Intravitreal Administration of AAV2-SIRT1 Reverses Diabetic Retinopathy in a Mouse Model of Type 2 Diabetes
por: Adu-Agyeiwaah, Yvonne, et al.
Publicado: (2023)

Ab-Externo AAV-Mediated Gene Delivery to the Suprachoroidal Space Using a 250 Micron Flexible Microcatheter
por: Peden, Marc C., et al.
Publicado: (2011)

Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
por: Mendell, Jerry R., et al.
Publicado: (2021)

Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dcn8b97j68fmmtgv8e1gg4ocpv